PA
APGE

Profund Advisors’s Apogee Therapeutics APGE Stock Holding History

Profund Advisors’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.28M Sell
17,163
-9,958
-37% -$897K 0.06% 169
2026
Q1 		$2.28M Buy
27,121
+8,845
+48% +$642K 0.08% 172
2025
Q4 		$1.38M Buy
18,276
+4,105
+29% +$259K 0.04% 278
2025
Q3 		$563K Buy
14,171
+5,190
+58% +$198K 0.02% 472
2025
Q2 		$390K Sell
8,981
-234
-3% -$8.9K 0.01% 553
2025
Q1 		$344K Sell
9,215
-2,221
-19% -$85.9K 0.02% 614
2024
Q4 		$518K Buy
11,436
+324
+3% +$16.5K 0.02% 499
2024
Q3 		$653K Sell
11,112
-2,898
-21% -$139K 0.02% 430
2024
Q2 		$551K Buy
14,010
+3,090
+28% +$150K 0.02% 473
2024
Q1 		$726K Buy
+10,920
New +$477K 0.03% 449

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Profund Advisors's APGE Position: Q2 2026 in Review

Profund Advisors reduced its Apogee Therapeutics (APGE) stake by 37% in Q2 2026, selling an estimated $897K and leaving 17,163 shares worth $2.28M. The position accounts for 0.06% of the portfolio, ranked #169.

Profund Advisors first reported a position in APGE in Q1 2024 and has held it in 10 quarters since. The position peaked at $2.28M in Q1 2026. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Profund Advisors held 17,163 shares of Apogee Therapeutics worth $2.28M as of Q2 2026.
  • Profund Advisors sold 9,958 Apogee Therapeutics shares in Q2 2026, an estimated $897K.
  • Apogee Therapeutics made up 0.06% of Profund Advisors's portfolio in Q2 2026, its #169 holding.
  • Profund Advisors first reported a position in Apogee Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Profund Advisors's Apogee Therapeutics position peaked at $2.28M in Q1 2026.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Profund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.